Melinda Gooderham

15.4k total citations · 5 hit papers
350 papers, 8.6k citations indexed

About

Melinda Gooderham is a scholar working on Dermatology, Immunology and Immunology and Allergy. According to data from OpenAlex, Melinda Gooderham has authored 350 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Dermatology, 187 papers in Immunology and 83 papers in Immunology and Allergy. Recurrent topics in Melinda Gooderham's work include Dermatology and Skin Diseases (190 papers), Psoriasis: Treatment and Pathogenesis (173 papers) and Allergic Rhinitis and Sensitization (61 papers). Melinda Gooderham is often cited by papers focused on Dermatology and Skin Diseases (190 papers), Psoriasis: Treatment and Pathogenesis (173 papers) and Allergic Rhinitis and Sensitization (61 papers). Melinda Gooderham collaborates with scholars based in Canada, United States and Germany. Melinda Gooderham's co-authors include Kim Papp, Andrew Blauvelt, Kristian Reich, Diamant Thaçi, Mark Lebwohl, Robert Bissonnette, Yves Poulin, Charles Lynde, Panteha Eshtiaghi and C. Paul and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Melinda Gooderham

315 papers receiving 8.5k citations

Hit Papers

Risankizumab versus Ustek... 2016 2026 2019 2022 2017 2016 2020 2021 2022 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
    2017 392 citations Kim Papp, Andrew Blauvelt et al. profile →
  2. Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
    2016 320 citations Robert Bissonnette, Kim Papp et al. British Journal of Dermatology profile →
  3. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
    2020 289 citations Jonathan I. Silverberg, Eric L. Simpson et al. profile →
  4. Bimekizumab versus Secukinumab in Plaque Psoriasis
    2021 230 citations Kristian Reich, Richard B. Warren et al. profile →
  5. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
    2022 219 citations April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Melinda Gooderham Canada 46 5.0k 4.9k 1.7k 1.6k 1.5k 350 8.6k
Yves Poulin Canada 44 4.7k 0.9× 3.9k 0.8× 1.0k 0.6× 774 0.5× 801 0.5× 169 7.1k
Diamant Thaçi Germany 56 7.7k 1.5× 8.3k 1.7× 3.2k 1.9× 2.7k 1.8× 2.5k 1.7× 375 13.5k
Richard B. Warren United Kingdom 49 3.4k 0.7× 6.2k 1.3× 1.9k 1.1× 340 0.2× 1.1k 0.7× 344 8.1k
Paolo Gisondi Italy 49 3.3k 0.7× 5.8k 1.2× 2.5k 1.5× 453 0.3× 782 0.5× 285 8.7k
Neil J. Korman United States 46 4.0k 0.8× 5.6k 1.1× 2.5k 1.5× 671 0.4× 780 0.5× 163 9.8k
Bruce Strober United States 53 5.1k 1.0× 7.6k 1.6× 2.0k 1.1× 392 0.3× 1.2k 0.8× 285 11.1k
Lotus Mallbris United States 40 2.1k 0.4× 3.5k 0.7× 1.2k 0.7× 337 0.2× 739 0.5× 96 4.8k
Knud Kragballe Denmark 53 3.6k 0.7× 5.2k 1.0× 866 0.5× 592 0.4× 1.2k 0.8× 256 9.2k
Gerald G. Krueger United States 52 3.6k 0.7× 7.7k 1.6× 3.1k 1.8× 296 0.2× 1.0k 0.7× 121 9.9k
Kenneth B. Gordon United States 61 7.7k 1.5× 13.8k 2.8× 3.3k 1.9× 539 0.3× 2.2k 1.5× 206 16.7k

Countries citing papers authored by Melinda Gooderham

Since Specialization
Citations

This map shows the geographic impact of Melinda Gooderham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melinda Gooderham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melinda Gooderham more than expected).

Fields of papers citing papers by Melinda Gooderham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melinda Gooderham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melinda Gooderham. The network helps show where Melinda Gooderham may publish in the future.

Co-authorship network of co-authors of Melinda Gooderham

This figure shows the co-authorship network connecting the top 25 collaborators of Melinda Gooderham. A scholar is included among the top collaborators of Melinda Gooderham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melinda Gooderham. Melinda Gooderham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cather, Jennifer Clay, Melodie Young, Shehla Admani, et al.. (2025). Genital Psoriasis: Shining Light on This Hidden Disease. JEADV Clinical Practice. 4(4). 719–731.
2.
Silverberg, Jonathan I., April W. Armstrong, Emma Guttman‐Yassky, et al.. (2025). Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials. American Journal of Clinical Dermatology. 27(1). 149–166.
3.
Lebwohl, Mark, Melinda Gooderham, Richard B. Warren, et al.. (2025). Outcomes of Psoriasis Area and Severity Index (PASI) and PASI components in two phase III trials of deucravacitinib in patients with moderate to severe plaque psoriasis. Clinical and Experimental Dermatology. 50(10). 2030–2036.
4.
Simpson, Eric L., Mark Boguniewicz, Lawrence F. Eichenfield, et al.. (2024). 53863 Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 clinical trials of adults and children with atopic dermatitis. Journal of the American Academy of Dermatology. 91(3). AB281–AB281.
5.
Gooderham, Melinda, Marjolein de Bruin‐Weller, Stephan Weidinger, et al.. (2024). Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations. Dermatology and Therapy. 14(8). 2285–2296. 3 indexed citations
6.
7.
Simpson, Eric L., Melinda Gooderham, Leon Kircik, et al.. (2024). 53652 Efficacy and safety of eblasakimab in adults with severe atopic dermatitis: a posthoc analysis of the Phase 2b TREK-AD trial. Journal of the American Academy of Dermatology. 91(3). AB194–AB194. 1 indexed citations
8.
King, Brett, Jennifer Soung, Christos Tziotzios, et al.. (2024). Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal of Clinical Dermatology. 25(2). 299–314. 27 indexed citations
9.
Reich, Kristian, Eric L. Simpson, Richard G. Langley, et al.. (2023). Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate to severe atopic dermatitis: including adverse events of special interest. SKIN The Journal of Cutaneous Medicine. 7(2). s143–s143. 1 indexed citations
10.
Schmid‐Grendelmeier, Peter, Melinda Gooderham, Karin Hartmann, et al.. (2023). Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies. Allergy. 79(1). 174–183. 2 indexed citations
11.
Puig, L., Siew Eng Choon, Alice B. Gottlieb, et al.. (2023). Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology. 37(4). 737–752. 39 indexed citations
12.
Adam, David N., Melinda Gooderham, Jennifer Beecker, et al.. (2023). Expert consensus on the systemic treatment of atopic dermatitis in special populations. Journal of the European Academy of Dermatology and Venereology. 37(6). 1135–1148. 42 indexed citations
13.
Simpson, Eric L., Lawrence F. Eichenfield, Melinda Gooderham, et al.. (2023). 390 Efficacy and safety of roflumilast cream 0.15% in adults and children aged ≥6 years with mild to moderate atopic dermatitis in two phase 3 trials (INTEGUMENT-1 and INTEGUMENT-2). British Journal of Dermatology. 188(Supplement_3). 1 indexed citations
14.
Lebwohl, Mark, Linda Stein Gold, Melinda Gooderham, et al.. (2023). Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial. SKIN The Journal of Cutaneous Medicine. 7(2). s111–s111. 1 indexed citations
15.
Wollenberg, Andreas, Melinda Gooderham, Norito Katoh, et al.. (2023). 328 Understanding the impact of atopic dermatitis on patients: a large international, ethnically diverse survey-based qualitative study. British Journal of Dermatology. 188(Supplement_2). 5 indexed citations
16.
Eichenfield, Lawrence F., Linda Stein Gold, Leon Kircik, et al.. (2023). Triple‐combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate‐to‐severe acne in children and adolescents: Randomized phase 2 study. Pediatric Dermatology. 40(3). 452–459. 7 indexed citations
17.
Kokolakis, Georgios, Richard B. Warren, Bruce Strober, et al.. (2022). Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. British Journal of Dermatology. 188(3). 330–340. 18 indexed citations
18.
Langley, Richard G., Petr Arenberger, Susan Flavin, et al.. (2020). 15302 Psoriasis area and severity index component improvements at week 48 in patients treated with guselkumab compared with secukinumab: Findings from the ECLIPSE study. Journal of the American Academy of Dermatology. 83(6). AB34–AB34. 3 indexed citations
19.
Gooderham, Melinda, et al.. (2018). Retrospective Study of 133 Canadian Hidradenitis Suppurativa Patients and Literature Review. 3(2). 1 indexed citations
20.
Bissonnette, Robert, Kim Papp, Yves Poulin, et al.. (2016). Topical tofacitinib for atopic dermatitis: a phase II a randomized trial. British Journal of Dermatology. 175(5). 902–911. 320 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yves Poulin Breakdown of academic impact, for papers by Diamant Thaçi Breakdown of academic impact, for papers by Richard B. Warren Breakdown of academic impact, for papers by Paolo Gisondi Breakdown of academic impact, for papers by Neil J. Korman Breakdown of academic impact, for papers by Bruce Strober Breakdown of academic impact, for papers by Lotus Mallbris Breakdown of academic impact, for papers by Knud Kragballe Breakdown of academic impact, for papers by Gerald G. Krueger Breakdown of academic impact, for papers by Kenneth B. Gordon
Rankless by CCL
2026